Suppr超能文献

霍奇金淋巴瘤后乳腺癌的局部区域治疗:保乳选择。

Locoregional treatment for breast carcinoma after Hodgkin's lymphoma: the breast conservation option.

机构信息

Department of Radiation Oncology, Institut Curie, Paris, France.

出版信息

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):e145-52. doi: 10.1016/j.ijrobp.2011.03.013. Epub 2011 May 24.

Abstract

PURPOSE

To report clinical and pathologic characteristics and outcome of breast cancer (BC) after irradiation for Hodgkin's lymphoma (HL) in women treated at the Institut Curie, with a special focus on the breast-conserving option.

METHODS AND MATERIALS

Medical records of 72 women who developed either ductal carcinoma in situ or Stage I-III invasive carcinoma of the breast after HL between 1978 and 2009 were retrospectively reviewed.

RESULTS

Median age at HL diagnosis was 23 years (range, 14-53 years). Median total dose received by the mediastinum was 40 Gy, mostly by a mantle-field technique. Breast cancers occurred after a median interval of 21 years (range, 5-40 years). Ductal invasive carcinoma and ductal carcinoma in situ represented, respectively, 51 cases (71%) and 14 cases (19%). Invasive BCs consisted of 47 cT0-2 tumors (82%), 5 cN1-3 tumors (9%), and 20 Grade 3 tumors (35%). Locoregional treatment for BCs consisted of mastectomy with (3) or without (36) radiotherapy in 39 patients and lumpectomy with (30) or without (2) adjuvant radiotherapy in 32 patients. The isocentric lateral decubitus radiation technique was used in 17 patients after breast-conserving surgery (57%). With a median follow-up of 7 years, 5-year overall survival rate and locoregional control rate were, respectively, 74.5% (95% confidence interval [CI], 64-88%) and 82% (95% CI, 72-93%) for invasive carcinoma and 100% (95% CI, 100 -100%) and 92% (95% CI, 79-100%) for in situ carcinoma. In patients with invasive tumors, the 5-year distant disease-free survival rate was 79% (95% CI, 69-91%), and 13 patients died of progressive BC. Contralateral BC was diagnosed in 10 patients (14%).

CONCLUSIONS

Breast-conserving treatment can be an option for BCs that occur after HL, despite prior thoracic irradiation. It should consist of lumpectomy and adjuvant breast radiotherapy with use of adequate techniques, such as the lateral decubitus isocentric position, to protect the underlying heart and lung.

摘要

目的

报告在居里研究所治疗的接受霍奇金淋巴瘤(HL)照射后发生乳腺癌(BC)的临床和病理特征及结果,尤其关注保乳选择。

方法和材料

回顾性分析 1978 年至 2009 年间 72 例 HL 后发生乳腺导管原位癌或 I-III 期浸润性乳腺癌的女性患者的病历资料。

结果

HL 诊断时的中位年龄为 23 岁(范围 14-53 岁)。纵隔接受的中位总剂量为 40Gy,主要采用斗篷野技术。乳腺癌发生的中位间隔时间为 21 年(范围 5-40 年)。浸润性乳腺癌和导管原位癌分别为 51 例(71%)和 14 例(19%)。浸润性 BC 包括 47 例 cT0-2 肿瘤(82%)、5 例 cN1-3 肿瘤(9%)和 20 例 3 级肿瘤(35%)。BC 的局部区域治疗包括 39 例患者行乳房切除术伴(3 例)或不伴(36 例)放疗,32 例患者行保乳切除术伴(30 例)或不伴(2 例)辅助放疗。在 17 例保乳手术后患者中使用了等中心侧卧位放射技术(57%)。中位随访 7 年,浸润性癌的 5 年总生存率和局部区域控制率分别为 74.5%(95%可信区间[CI],64-88%)和 82%(95% CI,72-93%),原位癌分别为 100%(95% CI,100-100%)和 92%(95% CI,79-100%)。在浸润性肿瘤患者中,5 年无远处疾病生存率为 79%(95% CI,69-91%),13 例患者死于进展性 BC。10 例(14%)患者诊断为对侧 BC。

结论

尽管先前有胸部照射,但 HL 后发生的 BC 仍可选择保乳治疗。它应包括保乳切除术和辅助乳房放疗,同时使用适当的技术,如侧卧位等中心位置,以保护下方的心脏和肺。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验